1. Home
  2. RYTM vs TWST Comparison

RYTM vs TWST Comparison

Compare RYTM & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RYTM
  • TWST
  • Stock Information
  • Founded
  • RYTM 2008
  • TWST 2013
  • Country
  • RYTM United States
  • TWST United States
  • Employees
  • RYTM N/A
  • TWST N/A
  • Industry
  • RYTM Biotechnology: Pharmaceutical Preparations
  • TWST Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • RYTM Health Care
  • TWST Health Care
  • Exchange
  • RYTM Nasdaq
  • TWST Nasdaq
  • Market Cap
  • RYTM 3.5B
  • TWST 3.1B
  • IPO Year
  • RYTM 2017
  • TWST 2018
  • Fundamental
  • Price
  • RYTM $56.07
  • TWST $41.31
  • Analyst Decision
  • RYTM Strong Buy
  • TWST Buy
  • Analyst Count
  • RYTM 10
  • TWST 10
  • Target Price
  • RYTM $66.90
  • TWST $52.50
  • AVG Volume (30 Days)
  • RYTM 380.5K
  • TWST 933.0K
  • Earning Date
  • RYTM 02-26-2025
  • TWST 02-03-2025
  • Dividend Yield
  • RYTM N/A
  • TWST N/A
  • EPS Growth
  • RYTM N/A
  • TWST N/A
  • EPS
  • RYTM N/A
  • TWST N/A
  • Revenue
  • RYTM $112,530,000.00
  • TWST $330,189,000.00
  • Revenue This Year
  • RYTM $66.58
  • TWST $22.59
  • Revenue Next Year
  • RYTM $44.63
  • TWST $17.62
  • P/E Ratio
  • RYTM N/A
  • TWST N/A
  • Revenue Growth
  • RYTM 81.55
  • TWST 25.85
  • 52 Week Low
  • RYTM $35.17
  • TWST $27.41
  • 52 Week High
  • RYTM $68.58
  • TWST $60.90
  • Technical
  • Relative Strength Index (RSI)
  • RYTM 42.18
  • TWST 33.83
  • Support Level
  • RYTM $56.03
  • TWST $43.93
  • Resistance Level
  • RYTM $58.65
  • TWST $48.58
  • Average True Range (ATR)
  • RYTM 1.87
  • TWST 3.60
  • MACD
  • RYTM -0.27
  • TWST -0.96
  • Stochastic Oscillator
  • RYTM 5.45
  • TWST 2.96

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.

About TWST Twist Bioscience Corporation

Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to realize opportunities ahead rapidly. Geographically, it derives a majority of its revenue from the United States.

Share on Social Networks: